Although there were no associations between use of SGLT-2 inhibitors and other cirrhosis complications—such as variceal bleeding, hepatic encephalopathy, hepatorenal syndrome, spontaneous bacterial peritonitis, and hypoglycemia—in this subgroup, we can attribute this to the relatively compensated status of this subpopulation. Here, SLC5A2 is linked to hepatorenal syndrome.